{
    "type": "ETF",
    "ucits": true,
    "replication_method": "synthetic",
    "swaps": true,
    "derivatives": true,
    "leverage": false,
    "inverse": false,
    "complex_factors": [
        "Unfunded swaps",
        "Synthetic replication",
        "Counterparty risk",
        "Non-physical replication",
        "Sector concentration (Biotech)",
        "No leverage but swap dependency"
    ],
    "classification": "complex",
    "supporting_data": "The Invesco NASDAQ Biotech UCITS ETF uses unfunded swap agreements to synthetically replicate the NASDAQ Biotechnology Index performance. The Fund holds a basket of equities that do not fully replicate the index and swaps the performance of these equities with the counterparty to achieve index returns. This introduces counterparty risk and derivative exposure inherent to synthetic replication. The KIID explicitly states the use of unfunded swaps and counterparty risk, and the factsheet confirms synthetic replication with swap contracts. There is no leverage or inverse exposure, and the risk rating is 6 out of 7, indicating a medium-high risk profile. The ETF invests in a concentrated sector (biotechnology), which may increase volatility but is not a complexity driver by itself. The PRIIPs KID does not include a comprehension warning but confirms the derivative and counterparty risks. Costs are straightforward with no performance fees but include swap fees embedded in the ongoing charges. The synthetic replication and swap usage are the primary drivers of complexity under MiFID II, as they introduce derivative counterparty risk and a non-linear relationship to the underlying index performance. The absence of leverage or capital protection features reduces complexity somewhat, but the swap structure mandates classification as complex."
}